Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Statement Condensed Statements Of Operations Unaudited [Line Items]
Product sales	$ 2,278,235	$ 2,326,976	$ 4,767,778	$ 4,248,334
Cost of products sold	744,108	854,005	1,556,152	1,516,951
Gross profit	1,534,127	1,472,971	3,211,626	2,731,383
Selling, general and administrative expenses	1,340,129	1,487,076	2,728,031	2,939,326
Research and development expenses	42,885	39,502	164,722	78,814
Total operating expenses	1,383,014	1,526,578	2,892,753	3,018,140
Income (loss) from operations	151,113	(53,607)	318,873	(286,757)
Other income (expenses)
Other income			17,543
Interest expense	(30,011)	(63,318)	(64,569)	(105,721)
Interest-Amortization of debt issuance	0.00	(1,532)	0	(3,065)
Loss on Earnings from Medical Joint Venture	(47,093)	(46,084)	(47,903)	(124,179)
Total other expenses	(77,104)	(110,934)	(94,119)	(232,965)
Net income (loss) applicable to common stockholders	$ 74,009	$ (164,541)	$ 224,754	$ (519,722)
Net income (loss) per share applicable to common stockholders –
Basic	$ 0.00	$ (0.01)	$ 0.01	$ (0.03)
Diluted	$ 0.00	$ (0.01)	$ 0.01	$ (0.03)
Weighted average shares outstanding and to be issued –
Basic	16,744,951	15,975,822	16,765,602	15,796,754
Diluted	17,056,219	15,975,822	17,124,936	15,796,754